Market Cap (In USD)
18.31 Million
Revenue (In USD)
-
Net Income (In USD)
-22.45 Million
Avg. Volume
52.71 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.4632-1.9
- PE
- -
- EPS
- -
- Beta Value
- 0.048
- ISIN
- US6036931029
- CUSIP
- 603693102
- CIK
- 1840229
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jennifer S. Buell Ph.D.
- Employee Count
- -
- Website
- https://minktherapeutics.com
- Ipo Date
- 2021-10-15
- Details
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
More Stocks
-
CG
-
BUR
-
HFR
-
KTTAW
-
ACSTAcasti Pharma Inc.
ACST
-
BYDGFBoyd Group Services Inc.
BYDGF
-
KEY-PIKeyCorp
KEY-PI
-
9956ANE (Cayman) Inc.
9956